EPO and anemia: In the EPOANE trial, which led to licensing of EPO alfa in the indication of low-risk MDS with anemia, erythroid hematological improvement (HI-E, IWG 2006) was achieved in 32% of EPO treated patients compared to 4% of patients receiving placebo.